Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.

O]ur companies have until June of 2028 to get there. That should not be a sigh of relief. That should be a, oh my gosh, we've ...

Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

24/7 Market News encourages readers and industry observers to obtain a copy of this month’s National Geographic to review the full feature and explore the scientific context in depth. Interested ...

This player's pipeline should keep growth going over the long run.

Shares of Fortress Biotech rose after the company said it has agreed to sell a Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million. Shares were up 14% to $3.84 in Monday ...

This biotech powerhouse could maintain its strength for the long term.

AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

Cambridge’s Kendall Square bills itself as “the most innovative square mile on the planet” — but it’s possible that less of that innovation is happening in Cambridge as life science firms outsource ...

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

Our mission has always been clear: to eliminate contaminated food products from reaching consumers by making food ...